Page 2 - PD-L1 EbookV2 Flip PDF
P. 2
Contents
Introduction ................................................................................................................................. 3
Test availability at launch can be underestimated, under-budgeted and under-resourced: An
example using real-time, real world analysis of PD-L1 ................................................................ 4
PD-L1: A chance to get things right? ........................................................................................... 8
Diagnostics ignored in targeted therapy pricing, access and value ........................................... 10
Complementary testing in PD-L1 – a groundbreaking concept? ................................................ 12
The return on investment of better CDx planning based on early PD-L1 observations in NSCLC
................................................................................................................................................. 17
The Knight’s move in PD-L1 chess ........................................................................................... 21
How big can Merck's Keytruda be in lung cancer? It’s too early to call in the PD-L1 arms race! 23
The PD-L1 case: Immune checkpoint inhibitors and the lack of robust biomarkers ................... 24
Leave no patient behind: How the FDA approval of Keytruda for specific biomarkers will put
laboratory testing in the front line .............................................................................................. 29
Page 2 of 31
